Published • loading... • Updated
Cerevance to Present Phase 2 Trial Results on OFF Time and Sleep‑Related Outcomes with ...
Summary by Hastings Tribune
1 Articles
1 Articles
Cerevance to Present Phase 2 Trial Results on OFF Time and Sleep‑Related Outcomes with ...
Post hoc analyses of two Phase 2 trials examine the potential benefits of solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, across Parkinson’s disease populationsPhase 2 adjunctive trial data showed a significant reduction in the frequency and duration of OFF time…
·Nebraska, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium

